<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936324</url>
  </required_header>
  <id_info>
    <org_study_id>DRM01B-ACN01</org_study_id>
    <nct_id>NCT01936324</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel</brief_title>
  <official_title>A Study of the Safety, Tolerability and Preliminary Efficacy of DRM01B Topical Gel in Healthy Volunteers and Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermira, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2a study.

      The purpose of Phase 1 was to evaluate the safety and tolerability of DRM01B Topical Gel in 6
      healthy volunteers.

      The purpose of Phase 2a was to assess the safety, tolerability and preliminary efficacy of
      DRM01B Topical Gel compared to vehicle in subjects with acne vulgaris on the face.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 in Phase 2a</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Mean absolute change in acne lesion counts (inflammatory) from baseline to Week 12 in Phase 2a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 in Phase 2a</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Mean absolute change in acne lesion counts (non-inflammatory) from baseline to Week 12 in Phase 2a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Who Achieved ≥ 2-grade Improvement in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 in Phase 2a</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percentage of subjects who achieved ≥ 2-grade improvement in the investigator global assessment of acne (IGA) from baseline to Week 12 in Phase 2a
Scoring Criteria for Investigator Global Assessment 0 - Clear skin with no inflammatory or noninflammatory lesions
- Almost clear; rare noninflammatory lesions with no more than one small inflammatory lesion
- Mild severity; greater than Grade 1; some noninflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions)
- Moderate severity; greater than Grade 2; up to many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion
- Severe; greater than Grade 3; up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olumacostat Glasaretil Gel, 7.5%, or Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olumacostat Glasaretil Gel, 7.5%</intervention_name>
    <description>Gel containing Olumacostat Glasaretil</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2a</arm_group_label>
    <other_name>DRM01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Olumacostat Glasaretil Gel, Vehicle</intervention_name>
    <description>Vehicle (placebo) gel</description>
    <arm_group_label>Phase 2a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase 1 Inclusion Criteria

          1. Signed informed consent

          2. Willing to comply with the requirements of the protocol

          3. Males or non-pregnant, non-lactating females

          4. Age ≥ 18 years

          5. Was in good health and free from any clinically significant disease, as determined by
             the investigator

          6. If female and of childbearing potential, was willing to use an accepted method of
             birth control during study participation and for 30 days after the last application of
             study drug. Females were considered to be of childbearing potential unless they had
             been surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation), had
             been diagnosed as infertile, had a same-sex partner or vasectomized male partner, were
             postmenopausal for at least 1 year, or were abstinent. Acceptable methods of birth
             control were defined as: abstinence, oral contraceptives, contraceptive
             patches/implants; Depo-Provera®, double barrier methods (e.g., condom and spermicide)
             or an intrauterine device (IUD). The birth control method must have been
             stable/unchanged for 30 days prior to baseline.

          7. If male, was vasectomized or agreed to use an accepted method of birth control with
             female partner during study participation and for 30 days after the last application
             of study drug.

        Phase 1 Exclusion Criteria

          1. Females who were pregnant, planning to become pregnant during the course of the study,
             or were breast-feeding

          2. Had a known hypersensitivity to DRM01B or its excipients

          3. Had any skin condition that may have interfered with the safety evaluations during the
             study

          4. Had a clinical chemistry or hematology laboratory value at screening that was
             considered clinically significant, in the opinion of the investigator

          5. Participated in an investigational drug study within 30 days prior to screening

          6. Were considered a poor medical risk because of other systemic diseases or active
             uncontrolled infections, in the opinion of the investigator. Any other condition
             which, in the judgment of the investigator, would put the subject at unacceptable risk
             for participation in the study.

        Phase 2a Inclusion Criteria

          1. Signed informed consent

          2. Willing to comply with the requirements of the protocol

          3. Male or non-pregnant, non-lactating females

          4. Age ≥ 18 years

          5. If female and of childbearing potential, was willing to use an accepted method of
             birth control during study participation and for 30 days after the last study drug
             application. Females were considered to be of childbearing potential unless surgically
             sterilized (hysterectomy, bilateral oophorectomy, tubal ligation), had been diagnosed
             as infertile, had same sex partner or vasectomized male partner, or were
             postmenopausal for at least 1 year. Acceptable methods of birth control were defined
             as: abstinence, oral contraceptives, contraceptive patches/implants; Depo-Provera®,
             double barrier methods (e.g., condom and spermicide) or an IUD. The birth control
             method must have been stable/unchanged for 12 weeks prior to baseline and must have
             remained unchanged during study participation.

          6. If male, was vasectomized or agreed to use an accepted method of birth control with
             female partner during study participation and for 30 days after the last study drug
             application.

          7. Subjects were in good health and free from any disease that, in the opinion of the
             investigator, would have put the subject at risk during participation in the study.

          8. Clinical diagnosis of facial acne vulgaris defined as:

               -  At least 20 inflammatory lesions

               -  At least 20 noninflammatory lesions

               -  IGA of 3 or greater

          9. Willing to refrain from using any treatments, other than the investigational product,
             including antibiotics, for acne present on the face. Topical acne treatments that did
             not have significant or measurable systemic absorption (e.g., benzoyl peroxide,
             salicylic acid) were allowed for treatment of acne of the back, shoulders, and chest
             only.

        Phase 2a Exclusion Criteria

          1. Females who were pregnant, planning to become pregnant during the course of the study,
             or breast-feeding

          2. Had a known hypersensitivity to DRM01B or its excipients

          3. Had any skin condition that may have interfered with evaluation of safety or acne
             vulgaris (e.g., rosacea; seborrheic dermatitis; perioral dermatitis;
             corticosteroid-induced acne or folliculitis)

          4. Had excessive facial hair that would have interfered with diagnosis or assessment of
             acne vulgaris

          5. Had excessive sun exposure, in the opinion of the investigator, or use of tanning
             booths

          6. Had active cystic acne or acne conglobata, acne fulminans, and secondary acne

          7. Had 2 or more active nodular lesions

          8. Had a clinical chemistry or hematology laboratory value at screening that was
             considered clinically significant, in the opinion of the investigator

          9. Participated in an investigational drug study within 30 days prior to screening

         10. Subjects who were a poor medical risk because of other systemic diseases or active
             uncontrolled infections, in the opinion of the investigator

         11. Any other condition that, in the judgment of the investigator, would have put the
             subject at unacceptable risk during participation in the study

         12. Treatment with over-the-counter (OTC) topical medications for the treatment of acne
             vulgaris including benzoyl peroxide, topical anti-inflammatory medications,
             corticosteroids, α-hydroxy/glycolic acid on the face within 2 weeks prior to baseline

         13. Treatment with systemic corticosteroids within 4 weeks prior to baseline (Note: use of
             intranasal and inhaled corticosteroids was allowed for seasonal allergies and asthma)

         14. Treatment with systemic antibiotics, systemic anti-acne drugs, or systemic
             anti-inflammatory drugs within 4 weeks prior to baseline

         15. Prescription topical retinoid use on the face within 4 weeks of baseline (e.g.,
             tretinoin, tazarotene, adapalene).

         16. Treatment with a new hormonal therapy or dose change to an existing hormonal therapy
             within 12 weeks prior to baseline. The dose and frequency of use of any hormonal
             therapy started more than 12 weeks prior to baseline must have remained unchanged
             throughout the study. Hormonal therapies included, but were not limited to, estrogenic
             and progestational agents, such as birth control pills.

         17. Prior use of androgen receptor blockers (such as spironolactone or flutamide)

         18. Oral retinoid use (e.g., isotretinoin) within 12 months prior to baseline or vitamin A
             supplements greater than 10,000 units/day within 6 months of baseline

         19. Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 8
             weeks or during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Drew</last_name>
    <role>Study Director</role>
    <affiliation>Dermira, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guildford Dermatology Specialist Inc</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultranova Skincare</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cosmetic &amp; Laser Surgery</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Dermatology</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 3B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research, Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research, Inc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena Medical Research</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermetologique du Quebec Metropolitain (CRDQ)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2013</study_first_posted>
  <results_first_submitted>January 31, 2019</results_first_submitted>
  <results_first_submitted_qc>January 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2019</results_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Olumacostat Glasaretil Gel, 7.5%, Phase 1</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers</description>
        </group>
        <group group_id="P2">
          <title>Olumacostat Glasaretil Gel, 7.5%, Phase 2a</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Olumacostat Glasaretil Gel, Vehicle, Phase 2a</title>
          <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olumacostat Glasaretil Gel, 7.5%, Phase 1</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers</description>
        </group>
        <group group_id="B2">
          <title>Olumacostat Glasaretil Gel, 7.5%, Phase 2a</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Olumacostat Glasaretil Gel, Vehicle, Phase 2a</title>
          <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="55"/>
            <count group_id="B4" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.0" spread="11.3"/>
                    <measurement group_id="B2" value="23.9" spread="6.1"/>
                    <measurement group_id="B3" value="26.5" spread="9.0"/>
                    <measurement group_id="B4" value="26.0" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type</title>
          <description>Fitzpatrick Skin Type is a scale to numerically classify skin color, defined by the response to ultraviolet (UV) light with the following categories:
Type I Burns easily, rarely tans Type II Burns easily, tans minimally Type III Burns moderately, tans gradually Type IV Burns minimally, tans well Type V Rarely burns, tans profusely Type VI Never burns, deeply pigmented</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Type I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type VI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 in Phase 2a</title>
        <description>Mean absolute change in acne lesion counts (inflammatory) from baseline to Week 12 in Phase 2a</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Olumacostat Glasaretil Gel, 7.5%, Phase 2a</title>
            <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Olumacostat Glasaretil Gel, Vehicle, Phase 2a</title>
            <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 in Phase 2a</title>
          <description>Mean absolute change in acne lesion counts (inflammatory) from baseline to Week 12 in Phase 2a</description>
          <population>Intent-to-Treat</population>
          <units>Lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.865" spread="1.107"/>
                    <measurement group_id="O2" value="-14.296" spread="1.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, baseline lesion count, and center.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 in Phase 2a</title>
        <description>Mean absolute change in acne lesion counts (non-inflammatory) from baseline to Week 12 in Phase 2a</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Olumacostat Glasaretil Gel, 7.5%, Phase 2a</title>
            <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Olumacostat Glasaretil Gel, Vehicle, Phase 2a</title>
            <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12 in Phase 2a</title>
          <description>Mean absolute change in acne lesion counts (non-inflammatory) from baseline to Week 12 in Phase 2a</description>
          <population>Intent-to-Treat</population>
          <units>Lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.131" spread="1.902"/>
                    <measurement group_id="O2" value="-12.357" spread="1.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, baseline lesion count, and center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Achieved ≥ 2-grade Improvement in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 in Phase 2a</title>
        <description>Percentage of subjects who achieved ≥ 2-grade improvement in the investigator global assessment of acne (IGA) from baseline to Week 12 in Phase 2a
Scoring Criteria for Investigator Global Assessment 0 - Clear skin with no inflammatory or noninflammatory lesions
- Almost clear; rare noninflammatory lesions with no more than one small inflammatory lesion
- Mild severity; greater than Grade 1; some noninflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions)
- Moderate severity; greater than Grade 2; up to many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion
- Severe; greater than Grade 3; up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Olumacostat Glasaretil Gel, 7.5%, Phase 2a</title>
            <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Olumacostat Glasaretil Gel, Vehicle, Phase 2a</title>
            <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Achieved ≥ 2-grade Improvement in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12 in Phase 2a</title>
          <description>Percentage of subjects who achieved ≥ 2-grade improvement in the investigator global assessment of acne (IGA) from baseline to Week 12 in Phase 2a
Scoring Criteria for Investigator Global Assessment 0 - Clear skin with no inflammatory or noninflammatory lesions
- Almost clear; rare noninflammatory lesions with no more than one small inflammatory lesion
- Mild severity; greater than Grade 1; some noninflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions)
- Moderate severity; greater than Grade 2; up to many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion
- Severe; greater than Grade 3; up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions</description>
          <population>Intent-to-Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0070</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by study center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Week 12</time_frame>
      <desc>The Total Participants at risk are based on the Safety Population defined as Participants who were randomized and received at least one confirmed dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Olumacostat Glasaretil Gel, 7.5%, Phase 1</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers</description>
        </group>
        <group group_id="E2">
          <title>Olumacostat Glasaretil Gel, 7.5%, Phase 2a</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Olumacostat Glasaretil Gel, Vehicle, Phase 2a</title>
          <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture Right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Reema Singh</name_or_title>
      <organization>Dermira, Inc.</organization>
      <phone>650-421-2951</phone>
      <email>reema.singh@dermira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

